Brief of Former Federal Circuit Chief Judge Paul R. Michel and Scholars of Law and Economics as Amici Curae in Support of Respondents, in Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc.

Authors

• Jess Miers, University of AkronFollow
• Emily Michiko Morris, University of AkronFollow
• Mark F. Schultz, University of AkronFollow
• Kristina M.L. Acri, Colorado College
• Bowman Heiden, UC Berkeley
• Joshua Kresh, IPPI: The IP Policy Institute
• Honorable Paul Michel, U.S. Court of Appeals for the Federal Circuit
• Kristen Jakobsen Osenga, University of Richmond
• Douglas Park, The University of AkronFollow
• Ted M. Sichelman, University of San Diego

Document Type

Court Filing

Publication Date

3-27-2026

Abstract

• Innovation in Identification and Clinical Trials Testing of New Indications Yields Great Public Benefits but Requires the Incentive of Patent Protection.
• Section viii [skinny label statemetnts] was Never Intended to be a Safe Harbor for Infringement of Method of Use Patents.
• Allowing this Case to Proceed Past the Rule 12 Stage will not Deter Section viii Carve-Outs. 

Comments

Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc., U.S. Supreme Court No. 24-889 

Recommended Citation

Miers, Jess; Michiko Morris, Emily; Schultz, Mark F.; Acri, Kristina M.L.; Heiden, Bowman; Kresh, Joshua; Michel, Honorable Paul; Osenga, Kristen Jakobsen; Park, Douglas; and Sichelman, Ted M., "Brief of Former Federal Circuit Chief Judge Paul R. Michel and Scholars of Law and Economics as Amici Curae in Support of Respondents, in Hikma Pharmaceuticals USA, Inc. v. Amarin Pharma, Inc." (2026). Akron Law Faculty Publications. 485.
https://ideaexchange.uakron.edu/ua_law_publications/485